Evidence from the spectrum of TGFBR1 mutations in MSSE shows that truncating mutations detected in patients with thoracic aortic aneurysms in the course of diagnostic testing must be viewed with caution and not used as the basis of predictive tests for relatives. This evidence concerns the gene TGFBR1 and thoracic aortic aneurysm.